canertinib has been researched along with geldanamycin in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (geldanamycin) | Trials (geldanamycin) | Recent Studies (post-2010) (geldanamycin) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 1,167 | 1 | 329 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alroy, I; Citri, A; Fry, DW; Grammatikakis, N; Lavi, S; Neckers, L; Patterson, C; Rubin, C; Xu, W; Yarden, Y | 1 |
1 other study(ies) available for canertinib and geldanamycin
| Article | Year |
|---|---|
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
Topics: Antineoplastic Agents; Benzoquinones; Cell Division; Cell Line; Endocytosis; Enzyme Inhibitors; Humans; Lactams, Macrocyclic; Morpholines; Neoplasms; Protein-Tyrosine Kinases; Quinones; Receptor, ErbB-2; Recombinant Proteins; Transfection; Ubiquitin | 2002 |